Kratom's link to liver injury is the best-documented serious health risk associated with its use. Unlike many claimed kratom harms that lack a clinical evidence base, drug-induced liver injury (DILI) from kratom has appeared in peer-reviewed case reports since 2011 and is listed in the NIH LiverTox database — the authoritative US reference for hepatotoxic compounds.
This article does not overstate the risk. Serious hepatotoxicity is not common among kratom users, and in most documented cases it resolves after stopping. But it is real, it follows a recognizable pattern, and knowing what symptoms to watch for can make the difference between a complication that resolves early and one that progresses.
TL;DR: Kratom has been associated with a cholestatic form of drug-induced liver injury (DILI) — impaired bile flow from the liver — in case reports reviewed by Teschke et al. (2016) and catalogued in the NIH LiverTox database. Serious hepatotoxicity is uncommon but documented. Jaundice (yellowing of skin or eyes), dark urine, and pale stools are same-day medical red flags — contact a doctor immediately if you notice them. In most documented cases, liver function normalizes after kratom cessation without permanent damage. Risk is associated with high-dose use, long duration, concurrent alcohol use, concurrent hepatotoxic medications, and pre-existing liver conditions.
What is drug-induced liver injury (DILI)?
Drug-induced liver injury (DILI) is liver damage caused by a medication, supplement, or herbal substance. It is the most common cause of acute liver failure in the US and the most frequent reason medications are withdrawn from the market after approval.
Kratom produces a specific DILI pattern: cholestatic hepatitis. Cholestatic DILI impairs bile flow from the liver rather than directly killing liver cells (the hepatocellular pattern). In cholestatic injury, bile backs up in the liver, causing the characteristic symptoms of jaundice, dark urine, pale stools, and itching. Lab findings show elevated bilirubin and alkaline phosphatase (ALP) alongside elevated liver enzymes (alanine aminotransferase / ALT, aspartate aminotransferase / AST).
This pattern distinguishes kratom hepatotoxicity from other causes of liver injury and has been consistently observed across the published case reports.
The evidence linking kratom to liver injury
Kapp et al. (2011) published the first documented case of kratom-associated cholestatic hepatitis in a German man who developed jaundice and elevated liver enzymes after regular kratom use. Cessation led to full resolution.
Teschke et al. (2016), in Liver International, conducted the first systematic case series review of kratom hepatotoxicity, analyzing 8 cases from the medical literature. The review applied standardized causality assessment criteria and concluded that the cases met criteria for probable kratom-induced liver injury, with the cholestatic pattern dominant.
NIH LiverTox — the National Institutes of Health's authoritative database of hepatotoxic drugs and supplements — has a dedicated kratom entry, classifying kratom as "likely" to cause liver injury based on the accumulated case report literature. Being listed in LiverTox is a significant signal; it means the hepatotoxicity has cleared the NIH's evidence threshold.
FDA: The FDA has referenced kratom hepatotoxicity in its import alerts and advisory communications. The agency's adverse event reporting system has received reports of kratom-associated liver injury.
The case report literature has continued to grow through the early 2020s, with additional documented cases in Europe and North America. This is not a single isolated event.
Symptoms that warrant same-day medical attention
The following symptoms indicate possible liver injury and require a same-day call to a doctor or urgent care visit. Do not wait to see if they resolve on their own.
| Symptom | What it indicates | Action | |---------|------------------|--------| | Yellowing of skin or eyes (jaundice) | Bile backing up in bloodstream; bilirubin accumulation | See a doctor same day | | Dark urine (cola or tea-colored) | Bilirubin excreted by kidneys; cholestatic sign | See a doctor same day | | Pale or clay-colored stools | Bile not reaching intestines; cholestatic sign | See a doctor same day | | Severe right upper quadrant pain | Liver capsule distension or gallbladder involvement | See a doctor same day | | Intense itching (pruritus) without rash | Bile salt accumulation under skin; cholestatic pattern | See a doctor within 1–2 days | | Fatigue and loss of appetite persisting 2+ weeks | Possible liver stress signal alongside other symptoms | See a doctor within 1 week |
If you notice jaundice, dark urine, or pale stools during kratom use or shortly after stopping, contact a doctor the same day. These are clinical red flags that warrant a liver enzyme panel and bilirubin measurement, not watchful waiting.
Who is most at risk?
The kratom hepatotoxicity case series are too small to establish a precise risk profile, but patterns in the reports suggest these factors are associated with higher risk:
High dose. Across the documented cases, most involve users taking higher doses of kratom. The higher the alkaloid load per day, the greater the hepatic burden.
Long duration of use. Most documented cases involve chronic daily use rather than occasional use. Duration appears to compound the dose-related risk.
Concurrent alcohol use. Alcohol is independently hepatotoxic. Combined use of kratom and alcohol creates an additive burden on the liver's detoxification capacity. Alcohol co-use is consistently noted as a risk amplifier in the hepatotoxicity literature for herbal compounds. See our piece on kratom and alcohol for the full picture on this combination.
Concurrent hepatotoxic medications or supplements. The liver processes all hepatotoxic compounds through the same metabolic pathways. Adding kratom to other hepatotoxic loads — acetaminophen (Tylenol), statins, kava, or other herbal supplements — creates compounded risk.
Pre-existing liver disease. Hepatitis (viral or alcoholic), fatty liver disease, or other existing liver conditions reduce the liver's reserve capacity. Any additional hepatotoxic exposure has less buffer.
Kratom extract and concentrate use. Extracts and concentrates contain higher alkaloid concentrations per dose than plain dried leaf. At equivalent volume, they deliver greater alkaloid load.
What happens to the liver after stopping kratom?
The most consistent finding across the kratom hepatotoxicity case reports is that liver function normalizes after cessation. This is the typical pattern for cholestatic DILI from herbal compounds: once the causative agent is removed, the liver's regenerative capacity handles the recovery.
Typical resolution timeline:
- ALT and AST (liver enzymes): typically normalize within 4–12 weeks of cessation
- Bilirubin: usually clears within 4–8 weeks; jaundice typically resolves in this window
- ALP (alkaline phosphatase): may take slightly longer to normalize than the other enzymes
- Subjective wellbeing: fatigue and appetite typically improve within 2–4 weeks as bilirubin clears
In most documented cases, recovery was complete without permanent liver damage, and without the need for hospitalization or advanced intervention.
Two important caveats:
First, there are rare cases of prolonged cholestasis — where bile flow impairment persists for months and requires active management. These are the exception, not the rule, but they reinforce why early medical evaluation is important when symptoms appear.
Second, if you develop liver injury from kratom and subsequently restart kratom use, there is an established risk of recurrence — and recurrence in DILI can be more severe than the initial episode. If liver injury is confirmed, do not restart kratom use.
If you are concerned about liver symptoms and want support accessing appropriate medical evaluation, findtreatment.gov lists addiction medicine providers who can help manage cessation and coordinate care with primary care or gastroenterology.
Coach Aria is a 12-week behavioral coaching program for kratom recovery. The program covers the full cessation arc — including the early medical considerations that matter most in the first weeks after stopping. Private, no meetings, runs at your pace.